Spring Bank Pharmaceuticals

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

F Star provides IT consulting, system planning and introduction support from the standpoint of financial institutions and customers.  F Star was founded in 2011 and was headquartered in Tokyo, Japan.

HOPKINTON, Mass., Nov.  20, 2019  (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has initiated dosing patients in a Phase 1 trial of SB 11285, the company’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist. The Phase 1 trial aims to evaluate safety, tolerability and initial anti-tumor activity of IV SB 11285 in patients with advanced solid tumors.

Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285

HOPKINTON, Mass., Nov.  12, 2019  (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll, chief executive officer, will present at the following investor conferences:

Spring Bank Announces Investor Conference Presentations for the Remainder of 2019

HOPKINTON, Mass., Sept.  23, 2019  (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll, President and Chief Executive Officer, and Jonathan Freve, Chief Financial Officer, will participate in a fireside chat and host one-on-one meetings with investors at the 2019 Cantor Fitzgerald Global Healthcare Conference, which is being held October 2-4, 2019 at the InterContinental New York Barclay Hotel.

Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY

HOPKINTON, Mass., Sept.  17, 2019  (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Dr. Thomas Hayman, MD, Ph.D., a resident in the Department of Therapeutic Radiology at Yale Cancer Center, will present at the 2019 ASTRO Annual Meeting. Dr. Hayman will discuss the results from the study of activating the STimulator of INterferon Genes (STING) pathway using SB 11285, Spring Bank’s intravenously (IV)-administered STING agonist development compound, in combination with radiation therapy.

Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank’s STING Agonist Development Compound, and Radiation Therapy in Cancer at the 2019 ASTRO Annual Meeting

As of late, it has definitely been a great time to be an investor in Spring Bank Pharmaceuticals, Inc. (SBPH).

Spring Bank Pharmaceuticals, Inc. (SBPH) Shares March Higher, Can It Continue?

Today, we take an in-depth look at Spring Bank Pharmaceuticals.

Spring Bank: An Interesting $5 Biotech Concern

News for Spring Bank Pharmaceuticals Stock (SBPH)